Effect of Tocilizumab on “Ventilator Free Days” Composite Outcome in SARS-CoV-2 Patients: A Retrospective Competing Risk Analysis
References
- World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [accessed 15 October 2020].
- Aletreby WT, Alharthy AM, Faqihi F, Mady AF, Ramadan OE, Huwait BM, et al. Dynamics of SARS CoV-2 outbreak in the Kingdom of Saudi Arabia: A predictive model. Saudi Crit Care J 2020;4:79–83. doi: 10.4103/sccj.sccj_19_20
- Mady A, Aletreby W, Abdulrahman B, Lhmdi M, Noor AM, Alqahtani SA, Soliman I, Alharthy A, Karakitsos D, Memish ZA. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series. Ann Med Surg (Lond). 2020 Dec;60:417–424. doi: 10.1016/j.amsu.2020.10.061.
- Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020 May 5:10.1002/jmv.25964. doi: 10.1002/jmv.25964.
- Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020 Sep 29;24(1):589. doi: 10.1186/s13054-020-03306-6.
- Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020. doi: 10.1002/jmv.25948.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. doi: 10.1016/S0140-6736(20)30566-3.
- Tian S, Hu W, Niu L, Liu H, Xu H, Xiao S-Y. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020 Feb 28;15:700–704. doi: 10.1016/j.jtho.2020.02.010
- Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 Jul;92(7):814–818. doi: 10.1002/jmv.25801.
- Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020 Sep;56(3):106103. doi: 10.1016/j.ijantimicag.2020.106103.
- US Food and Drug Administration. ACTEMRA (Tocilizumab) Injection, for Intravenous or Subcutaneous Use. US Food and Drug Administration; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf
- Schoenfeld DA, Hayden D, Oldmixon C, Ringwood N, Thompson BT. Statistical design and analysis issues for the ARDS Clinical Trials Network: the coordinating center perspective. Clin Invest 2012;2:275–289. doi: 10.4155/CLI.12.14
- Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997 Jul;112(1):164–72. doi: 10.1378/chest.112.1.164.
- Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in critical care research. Am J Respir Crit Care Med. 2019 Oct 1;200(7):828–836. doi: 10.1164/rccm.201810-2050CP.
- Aletreby WT, Mumtaz SA, Al Harthy AM, Shahzad SA, Ramadan OE, Mady AF, et al. Outcome of early mobilization of critically ill patients: A propensity score matching trial. J Intensive & Crit Care. 2018, 4(3); 13. doi: 10.21767/2471-8505.100115
- Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007 Mar 15;165(6):710–8. doi: 10.1093/aje/kwk052.
- Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509. doi: 10.1080/01621459.1999.10474144
- Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo controlled clinical trial of an aerosolized b2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184:561–568. doi: 10.1164/rccm.201012-2090OC.
- Bein T, Weber-Carstens S, Goldmann A, Müller T, Staudinger T, Brederlau J, et al. Lower tidal volume strategy (_3 ml/kg) combined with extracorporeal CO2 removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med 2013;39:847–856. doi: 10.1007/s00134-012-2787-6.
- Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al.; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018;378: 809–818. doi: 10.1056/NEJMoa1705716.
- Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, Toko L, et al; HNF Hospital Tocilizumab multidisciplinary team. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Aug 13;99:491–495. doi: 10.1016/j.ijid.2020.08.024.
- Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020 Oct;2(10):e603–e612. doi: 10.1016/S2665-9913(20)30277-0.
- Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020 Jul 11:ciaa954. doi: 10.1093/cid/ciaa954.
- Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C, Sönnerborg A, et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. J Intern Med. 2020 Aug 3:10.1111/joim.13162. doi: 10.1111/joim.13162.
- REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Feb 25:NEJMoa2100433. doi: 10.1056/NEJMoa2100433.
- Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, Machado FR, Lopes RD, Berwanger O, Azevedo LCP, Avezum Á, Lisboa TC, Rojas SSO, Coelho JC, Leite RT, Carvalho JC, Andrade LEC, Sandes AF, Pintão MCT, Castro CG Jr, Santos SV, de Almeida TML, Costa AN, Gebara OCE, de Freitas FGR, Pacheco ES, Machado DJB, Martin J, Conceição FG, Siqueira SRR, Damiani LP, Ishihara LM, Schneider D, de Souza D, Cavalcanti AB, Scheinberg P; Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
- Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021 Feb 25:NEJMoa2028700. doi: 10.1056/NEJMoa2028700.
- Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474–e484. doi: 10.1016/S2665-9913(20)30173-9.
Language: English
Page range: 1 - 7
Published on: Jan 14, 2023
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2023 Ahmed F. Mady, Basheer Abdulrahman, Shahzad A. Mumtaz, Mohammed A. Al-Odat, Ahmed Kuhail, Rehab Altoraifi, Rayan Alshae, Abdulrahman M. Alharthy, Dimitrios Karakitsos, Waleed Th. Aletreby, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.